These may include the following considerations (1): National Comprehensive Cancer Network (NCCN) 2025 v3 guidelines recommend human epidermal growth factor receptor-2 (HER-2) immunohistochemistry (IHC) testing for advanced, metastatic, or recurrent cervical carcinoma, with reflex to HER-2 fluorescence in situ hybridization (FISH) if IHC results are inconclusive (2). This evidence concerns the gene ERBB2 and cervical carcinoma.